[go: up one dir, main page]

US3894001A - 11-Aminoalkyl- and 11-cyclicaminomorphanthridines - Google Patents

11-Aminoalkyl- and 11-cyclicaminomorphanthridines Download PDF

Info

Publication number
US3894001A
US3894001A US307933A US30793372A US3894001A US 3894001 A US3894001 A US 3894001A US 307933 A US307933 A US 307933A US 30793372 A US30793372 A US 30793372A US 3894001 A US3894001 A US 3894001A
Authority
US
United States
Prior art keywords
hydrogen
chloro
morphanthridine
methyl
dihydromorphanthridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US307933A
Inventor
Alexander E Drukker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Colgate Palmolive Co
Original Assignee
Colgate Palmolive Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Colgate Palmolive Co filed Critical Colgate Palmolive Co
Priority to US307933A priority Critical patent/US3894001A/en
Application granted granted Critical
Publication of US3894001A publication Critical patent/US3894001A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/20—Dibenz [b, e] azepines; Hydrogenated dibenz [b, e] azepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • AESTMW continuatiomimpart of Ser. No. 848,355, Aug. 7, The compounds are 1l-ammoalkylm0rphanthrldmes 1969, Pat 3,699,099, and a continuatiomimpart and ll-cyclicaminomorphanthridines which are useful f 48506, J 22 97 abandoned as central nervous system depressants of the tranquilizing type, muscle relaxants and analgetic agents.
  • X and Y are members of the group consisting of hydrogen, halogen such as chloro, bromo and fluoro, an alkyl of l to 4 carbon 'atoms'such as'methyl and ethyl, an alkoxy of l to 3 carbon atoms such as methoxy, ethoxy and propo'xy, a thio-lower alkyl such, as thiomethyl and thioethyl and trifluoromethyl, R, R and R are hydrogen or a lower alkyl of--1 :to 4 carbon atoms, n is 0 to 4 and Am is se'lectedfrom't.
  • R and R are selected from hydrogen, lower alkyl of l to 4 carbon atoms such as methyl, ethyl or isopropyl and a phenyl-lower alkyl of 7 to '13 carbon atoms such as benzyl, phenethyl or phenyliso'propyl, or
  • a heterocyclicamino group suchlas morpholino, pyrrolidino, piperidino, N-lower alkyl piperazino in which the lower alkyl is 1 to 4'carbon atoms such as N- methyl piperazino, N-phenyl-lower alkyl piperazino in which the lower alkyl is l to 4 carbon atorns such as N- benzyl piperazino and N-(hydroXy-lower alkyl)- piperazino groups in which the lower alkyl is Ho 4 carbon atoms such as 4-(B-hydroxyethyl piperazino), and
  • a c yclicamino group such as 3-'piper idyl', 4-pi peridyl, 3-pyrrolidyl, 3-homopiperidyl and 4-homopiperidyl.
  • the compounds of the present invention may be conveniently prepared from the corresponding 1 laminoalkyl-S,o-dihydromorphanthridines and the 11- cyclicamino -5,o dihydromorphanthrid ines which have the following formulae in w 'ch X, Y, R, R 1R n, Am and -C are as previously defined.
  • Representative of the compounds which may be employed as starting materials are l 1-( 3-dimethylaminopropyl )-5 ,-dihydromorphanthridine, 2-chloro-1 l-( 3-dimethylaminopropyl)-5 ,6-dihydromorphanthridine, S-chloro-l l-(3-dimethylaminopropyl)-5,6-dihydromorphanthridine, Z-trifluoromethyl-l l-( 3-dimethylaminopropyl )-5 ,6- dihydromorphanthridine, l 1-(3-diethylaminopropyl)-5,o-dihydromorphanthridine, Z-chloro-l l-(3diethylaminopropyl)-5,6-dihydromorphanthridine, 8-chloro-1 1-(3-diethylaminopropyl)-5,6-dihydromorphanthridine, Z
  • dihydromorphanthridine l 1,-(3-methylarninopropyl)-5,6-dihydromorphanthridine, 2-chloro-l l-(3-methylaminopropyl)-5,6-dihydromorphanthridine, S-chloro-l l-(3-methylaminopropyl)-5 ,6-dihydromorphanthridine, 2-trifluoromethyl-l l-(3-methylaminopropyl)-5,6-
  • dihydromorphanthridine 2-trifluoromethyl-l l-( N-methyl-N- benzylaminopropyl)-5,6-dihydromorphanthridine, l l-(N-methyl-piperazinopropyl)-5 ,6-dihydromorphanthridine, 2-chloro-1 l-(N-methyl-piperazinopropyl)-5 ,6-dihydromorphanthridine,
  • the compounds of the present invention have been found to possess utility as pharmaceutical and veterinary agents, especially as central nervous system depressants.
  • central nervous system depressants for example, in mouse behavioral studies the compound 1 1-(3-dimethylaminopropyl) morphanthridine was found in a dose of 10 mg/kg intraperitoneally to cause central nervous system depression. The studies also indicated that the compound had an LD in excess of 100 mg/kg intraperitoneally.
  • the forementioned compound was also tested for tranquilizing activity in mice which had been isolated to induce an antisocial aggressive behavior. in the tests the compound was administered to the mice in doses of 5 and 20 mg/kg intraperitoneally and found to have an E10 of about 20 mg/kg. The compound was also tested for analgetic activity in mice and was found to be effective against the effects of electrical stimulation in doses of 40 mg/lcg intraperitoneally.
  • the compounds When employed as pharmaceutical agents the compounds are preferably used in the form of acid addition salts.
  • Such acid addition salts may be conveniently prepared by conventional means such as by contacting the compounds with a suitable acid in a mutual solvent and then removing the solvent to obtain the desired salt.
  • acids which may be used are hydrochloric acid, succinic acid, tartaric acid, benzoic acid or fumaric acid.
  • Quarternary ammonium salts of the compounds may be formed by conventional techniques employing a suitable alkylating agent such as methyl chloride, methyl iodide or ethyl bromide.
  • Pharmaceutical dosage forms containing the active ingredients are generally prepared by combining the active ingredient or ingredients with a major amount of one or more suitable pharmaceutical diluents and then forming the resulting mixture into unit dosage forms suitable for oral or parenteral administration.
  • the unit dosage forms will generally contain from 5 to 250 mg. of the active ingredients. One or more of such units may be administered daily depending upon the patients physical size and the severity of the condition being treated. However, generally the daily dosage will not exceed 150 mg. of the active ingredient per kilogram of the patients body weight.
  • Suitable pharmaceutical composition which may be prepared are the following:
  • EXAMPLE 1 l 1-(3-Dimethylaminopropyl)morphanthridine Active manganese dioxide (25 grams) is refluxed with 250 ml. of benzene using a water separator. After 2 hours, 5.3 grams (0.019 mole) of 11-(3- dimethylaminopropy1)-5,6-dihydromorphanthridine in ml. of benzene is added and the suspension stirred and refluxed for 18 hours. The Mn0 is filtered off, rinsed with benzene, and the filtrate concentrated to yield the crude base. Chromatography over silica gel using benzene-methanol (19:1) as eluent followed by benzene-diethylamine (40: 1) affords 1 1-(3- dimethylaminopropyl)morphanthridine.
  • Example 2 The process of Example 1 is repeated employing in place of l 1-(3-dimethylaminopropyl)-5,o-dihydromorphanthridine one of the following:
  • R;, and R are hydrogen, alkyl of l to 4 carbons 0T p y alkyl 0f 7 to 13 carbons and R and R are hydrogen, alyl of 1 to 4 carbons or or benzyl.
  • yq r amlrw rq p Selected from q P o.
  • lino, pyrrolidlno, prperldino, N-lower alkyl pipera- Y, R R d R are hydrogen, n is 0, Am is zino, N-phenyl-lower alkyl piperazino and N- LhyfIlroxy-lower alkyl) -piperazino, and
  • cyclicamino group selected from 3-piperidyl, 4- ⁇ R1 piperidyl, 3-pyrrolidyl, 3-homopiperidyl and 4- homopiperidyl and pharmaceutically acceptable acid addition salts thereof,

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The compounds are 11-aminoalkylmorphanthridines and 11cyclicaminomorphanthridines which are useful as central nervous system depressants of the tranquilizing type, muscle relaxants and analgetic agents. Representative of the compounds disclosed are 11-(3-dimethylaminopropyl)morphanthridine and 11-(N-methyl-4piperidyl)morphanthridine. The method of preparing the compounds is by the oxidation of the corresponding 5,6dihydromorphanthridine with active manganese dioxide.

Description

United States Patent [1 1 [111 33%,001 Drukker July 8 1975 ll-AMINOALKYL- AND [56] References Cited 11 l-CYCLICAMINOMORPHANTHRIDINES UNITED STATES PATENTS [7 5] Inventor: Alexander E. Drukker, Milwaukee, 3,317,537 5/1967 Drukker 260/239 D Wis.
[73] Assignee: Colgate-Palmolive Company, New Primary Examifer Henry mes York Assistant Exammer-Robert T. Bond Attorney, Agent, or Firm-T. F. Kryshak; M. L. [22] Filed: Nov. 20, 1972 Youngs [21] Appl. No: 307,933
Related U.S. Application Data [57] AESTMW [63] continuatiomimpart of Ser. No. 848,355, Aug. 7, The compounds are 1l-ammoalkylm0rphanthrldmes 1969, Pat 3,699,099, and a continuatiomimpart and ll-cyclicaminomorphanthridines which are useful f 48506, J 22 97 abandoned as central nervous system depressants of the tranquilizing type, muscle relaxants and analgetic agents. Rep- [52] Us. C1 ..260/239 D; 260/247.1 M; resentative 0f the Compounds disclosed are H 260/247.5 R; 260/326.5 CA; 260/326.81; dimethylaminopropyl)morphanthridine and 260/268 TR; 424/244; 424/248; 424/250; methyl-4-piperidyl)morphanthridine. The method of 424/2 7; 424/274; 2 0/293 59 preparing the compounds is by the oxidation of the [51] Int. Cl C07d 41/08 Corresponding y 0 p r n w [58] Field of Search. 260/239 D, 247.1 M, 247.5 R, rive manganese dioxide- 260/326.5 CA, 326.81, 268 TR, 293.59
11% Claims, No Drawings RELATED CASES This application is a continuation in-part of my pending applications Ser. Nos. 848,355 now U.S. Pat. No. 3,699,099 and 48,506, now abandoned, filed Aug.
7, 1969, and June 22, 1970, respectively.
DESCRIPTION OF Til-IE INVENTION The compounds of the present invention may be represented by the following formulae:
in which X and Y are members of the group consisting of hydrogen, halogen such as chloro, bromo and fluoro, an alkyl of l to 4 carbon 'atoms'such as'methyl and ethyl, an alkoxy of l to 3 carbon atoms such as methoxy, ethoxy and propo'xy, a thio-lower alkyl such, as thiomethyl and thioethyl and trifluoromethyl, R, R and R are hydrogen or a lower alkyl of--1 :to 4 carbon atoms, n is 0 to 4 and Am is se'lectedfrom't.
in which R and R; are selected from hydrogen, lower alkyl of l to 4 carbon atoms such as methyl, ethyl or isopropyl and a phenyl-lower alkyl of 7 to '13 carbon atoms such as benzyl, phenethyl or phenyliso'propyl, or
b. a heterocyclicamino group suchlas morpholino, pyrrolidino, piperidino, N-lower alkyl piperazino in which the lower alkyl is 1 to 4'carbon atoms such as N- methyl piperazino, N-phenyl-lower alkyl piperazino in which the lower alkyl is l to 4 carbon atorns such as N- benzyl piperazino and N-(hydroXy-lower alkyl)- piperazino groups in which the lower alkyl is Ho 4 carbon atoms such as 4-(B-hydroxyethyl piperazino), and
is a c yclicamino group such as 3-'piper idyl', 4-pi peridyl, 3-pyrrolidyl, 3-homopiperidyl and 4-homopiperidyl.
The compounds of the present invention may be conveniently prepared from the corresponding 1 laminoalkyl-S,o-dihydromorphanthridines and the 11- cyclicamino -5,o dihydromorphanthrid ines which have the following formulae in w 'ch X, Y, R, R 1R n, Am and -C are as previously defined.
Representative of the compounds which may be employed as starting materials are l 1-( 3-dimethylaminopropyl )-5 ,-dihydromorphanthridine, 2-chloro-1 l-( 3-dimethylaminopropyl)-5 ,6-dihydromorphanthridine, S-chloro-l l-(3-dimethylaminopropyl)-5,6-dihydromorphanthridine, Z-trifluoromethyl-l l-( 3-dimethylaminopropyl )-5 ,6- dihydromorphanthridine, l 1-(3-diethylaminopropyl)-5,o-dihydromorphanthridine, Z-chloro-l l-(3diethylaminopropyl)-5,6-dihydromorphanthridine, 8-chloro-1 1-(3-diethylaminopropyl)-5,6-dihydromorphanthridine, Z-trifluoromethyl-l l-( 3-diethy laminopropyl)-5 ,6-
dihydromorphanthridine, l 1,-(3-methylarninopropyl)-5,6-dihydromorphanthridine, 2-chloro-l l-(3-methylaminopropyl)-5,6-dihydromorphanthridine, S-chloro-l l-(3-methylaminopropyl)-5 ,6-dihydromorphanthridine, 2-trifluoromethyl-l l-(3-methylaminopropyl)-5,6-
dihydromorphanthridine, l l-(N-methyl-N-benzylaminopropyl)-5,6-dihydromorphanthridine, 2-chloro-l 1-(N-methyl-N-benzylaminopropyl)-5 ,6- dihydromorphanthridine, 8-chloro-1 1-(N-methyl-N-benzylaminopropyl)-5 ,6-
dihydromorphanthridine, 2-trifluoromethyl-l l-( N-methyl-N- benzylaminopropyl)-5,6-dihydromorphanthridine, l l-(N-methyl-piperazinopropyl)-5 ,6-dihydromorphanthridine, 2-chloro-1 l-(N-methyl-piperazinopropyl)-5 ,6-dihydromorphanthridine,
5 8-chloro-l l-(N-methyl-piperazinopropyl)-5 ,6-dihydromorphanthridine,
Z-trifluoromethyl-l 1-( N-methyl-piperazinopropyl)- 5 ,6-dihydromorphanthridine,
1 1-[ 3-(4-hydroxyethylpiperazinopropyl) ]-5 ,6-dihydromorphanthridine, I
l l-[ 3-(4-hydroxyethylpiperazinopropyl)]- morphanthridine,
Z-chloro-l l-[ 3-(4-hydroxyethylpiperazinopropyl) morphanthridine,
8-chloro-l 1-[3-(4-hydroxyethylpiperzinopropyl)]- morphanthridine,
Z-trifluoromethyl-l 1-[3-(4- hydroxyethylpiperazinopropyl) ]-morphanthridine,
l l-(N-methyl-4-piperidyl)-morphanthridine, 2-chloro-1 1-(N-methyl-4-piperidyl)- morphanthridine,
8-chloro-l l-( N-methyl-4-piperidyl morphanthridine,
2-trifluoromethyl- 1 l-(N-methyl-4-piperidyl morphanthridine,
1 l-(N-benzyl-4-piperidyl)-morphanthridine, 2-chloro-1 1(N-benzyl-4-piperidyl)- morphanthridine,
8-chloro-1 l-(N-benzyl-4-piperidyl)- morphanthridine,
2-trifluoromethyl-1 1-( N-benZyl-4-piperidyl morphanthridine,
l l-(l\l-methyl-3-piperidyl)-morphanthridine,
2-chloro-l l-(N-methyl-3-piperidyl)- moi-phanthridine,
8-chloro-l 1-(N-methyl-3-piperidyl)- morphanthridine,
Z-trifluoromethyl-l 1-( N-methyl-3-piperidyl morphanthridine,
1 l-(N-ethyl-3-pyrrolidyl)-morphanthridine,
l l-(N-benzyl-3-pyrrolidyl)-morphanthridine, and
l l-(N-methyl-3-homopiperidyl)-morphanthridine.
The compounds of the present invention have been found to possess utility as pharmaceutical and veterinary agents, especially as central nervous system depressants. For example, in mouse behavioral studies the compound 1 1-(3-dimethylaminopropyl) morphanthridine was found in a dose of 10 mg/kg intraperitoneally to cause central nervous system depression. The studies also indicated that the compound had an LD in excess of 100 mg/kg intraperitoneally.
The forementioned compound was also tested for tranquilizing activity in mice which had been isolated to induce an antisocial aggressive behavior. in the tests the compound was administered to the mice in doses of 5 and 20 mg/kg intraperitoneally and found to have an E10 of about 20 mg/kg. The compound was also tested for analgetic activity in mice and was found to be effective against the effects of electrical stimulation in doses of 40 mg/lcg intraperitoneally.
When employed as pharmaceutical agents the compounds are preferably used in the form of acid addition salts. Such acid addition salts may be conveniently prepared by conventional means such as by contacting the compounds with a suitable acid in a mutual solvent and then removing the solvent to obtain the desired salt. Examples of acids which may be used are hydrochloric acid, succinic acid, tartaric acid, benzoic acid or fumaric acid.
Quarternary ammonium salts of the compounds may be formed by conventional techniques employing a suitable alkylating agent such as methyl chloride, methyl iodide or ethyl bromide.
Pharmaceutical dosage forms containing the active ingredients are generally prepared by combining the active ingredient or ingredients with a major amount of one or more suitable pharmaceutical diluents and then forming the resulting mixture into unit dosage forms suitable for oral or parenteral administration.
The unit dosage forms will generally contain from 5 to 250 mg. of the active ingredients. One or more of such units may be administered daily depending upon the patients physical size and the severity of the condition being treated. However, generally the daily dosage will not exceed 150 mg. of the active ingredient per kilogram of the patients body weight.
Representative of a suitable pharmaceutical composition which may be prepared are the following:
TABLETS l l-(3-Dimethylaminopropyl) morphanthridine 2 Methyl cellulose, 400 cps. Lactose Magnesium stearate Starch The powders, other than magnesium stearate, are granulated with water, passed through a No. 16 mesh screen and dried at 50 C. Magnesium stearate is mixed in and 40 mg. tablets are pressed.
The practice of the invention is further illustrated by the following examples:
EXAMPLE 1 l 1-(3-Dimethylaminopropyl)morphanthridine Active manganese dioxide (25 grams) is refluxed with 250 ml. of benzene using a water separator. After 2 hours, 5.3 grams (0.019 mole) of 11-(3- dimethylaminopropy1)-5,6-dihydromorphanthridine in ml. of benzene is added and the suspension stirred and refluxed for 18 hours. The Mn0 is filtered off, rinsed with benzene, and the filtrate concentrated to yield the crude base. Chromatography over silica gel using benzene-methanol (19:1) as eluent followed by benzene-diethylamine (40: 1) affords 1 1-(3- dimethylaminopropyl)morphanthridine.
Anal. Calcd. for C l-ll N C, 81.97; H, 7.97; N, 10.06.
Found: C, 82.24; H, 8.31; N, 10.22.
EXAMPLE 2 The process of Example 1 is repeated employing in place of l 1-(3-dimethylaminopropyl)-5,o-dihydromorphanthridine one of the following:
2-chloro-1 l-(3-dimethylaminopropyl)-5,6-dihydromorphanthridine,
8-chloro-1 1-( 3-dirnethylaminopropyl )-5 ,6-dihydromorphanthridine,
2-trifluoromethyl-l l-(3-dimethylaminopropyl)-5,6-
9 W R R Y X Y CHR (CHR Am c I II in which X and Y are hydrogen, halo, alkoxy of 1 to 3 and R and R are hydrogen, alkyl of l to 4 carbons or carbons, alkyl of l to 4 carbons, thio-lower alkyl or tribenzyl. fluoromethyl, n is to 4, R, R and R are hydrogen or 5. A compound of Formula II of claim 1 in which X, alkyl of 1 to 4 carbon atoms, Am is Y, R, R and R are hydrogen, n is 0, Am is a. N R,,
in which R;, and R are hydrogen, alkyl of l to 4 carbons 0T p y alkyl 0f 7 to 13 carbons and R and R are hydrogen, alyl of 1 to 4 carbons or or benzyl. yq r amlrw rq p Selected from q P o. A compound of Formula 1 of claim 1 m which x,
lino, pyrrolidlno, prperldino, N-lower alkyl pipera- Y, R R d R are hydrogen, n is 0, Am is zino, N-phenyl-lower alkyl piperazino and N- LhyfIlroxy-lower alkyl) -piperazino, and
is a cyclicamino group selected from 3-piperidyl, 4- \R1 piperidyl, 3-pyrrolidyl, 3-homopiperidyl and 4- homopiperidyl and pharmaceutically acceptable acid addition salts thereof,
2. A compound of Formula I of claim 1 in which X and Y are hydrogen or chloro.
and 1R and R are methyl.
7. A compound of Formula I of claim l in which X is hydrogen, Y is chloro, R, R and R are hydrogen, n
3. A compound of Formula I of claim 1 in which X is Am is and Y are hydrogen or chloro, R, R and R are hydrogen, n is 0, Am is R3 R a R and R and R are methyl.
and 3 and 4 are hydrogen, alkyl of 1 t0 4 carbons 8. A compound of Formula II of claim l in lwhich X benzyl. and Y are hydrogen.
A Compound of Formula I of clam 1 Whlch X 9. A compound of Formula II of claim 1 in which X is hydrogen, Y is chloro, R, R and R are hydrogen, n is hydrogen and Y is ch10r0 IS 0, Am 1s 10. A compound of Formula II of claim 1 in which X andxare hydrogen or chloro, /Rn is 3 or 4-piperidyl and R is an alkyl of 1 to 4 carbons.

Claims (10)

1. A COMPOUND SELECTED FROM COMPOUNDS OF THE FORMULAE:
2. A compound of Formula I of claim 1 in which X and Y are hydrogen or chloro.
3. A compound of Formula I of claim 1 in which X and Y are hydrogen or chloro, R, R1 and R2 are hydrogen, n is 0, Am is
4. A compound of Formula I of claim 1 in which X is hydrogen, Y is chloro, R, R1 and R2 are hydrogen, n is 0, Am is
5. A compound of Formula I of claim 1 in which X, Y, R, R1 and R2 are hydrogen, n is 0, Am is
6. A compound of Formula I of claim 1 in which X, Y, R, R1 and R2 are hydrogen, n is 0, Am is
7. A compound of Formula I of claim 1 in which X is hydrogen, Y is chloro, R, R1 and R2 are hydrogen, n is 0, Am is
8. A compouNd of Formula II of claim 1 in lwhich X and Y are hydrogen.
9. A compound of Formula II of claim 1 in which X is hydrogen and Y is chloro.
10. A COMPOUND OF FORMULA II OF CLAIM 1 IN WHICH X AND Y ARE HYDROGEN OR CHLORO, -C NIS 3 OR 4-PIPERIDYL AND R1 IS AN ALKYL OF 1 TO 4 CARBONS.
US307933A 1969-08-07 1972-11-20 11-Aminoalkyl- and 11-cyclicaminomorphanthridines Expired - Lifetime US3894001A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US307933A US3894001A (en) 1969-08-07 1972-11-20 11-Aminoalkyl- and 11-cyclicaminomorphanthridines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84835569A 1969-08-07 1969-08-07
US307933A US3894001A (en) 1969-08-07 1972-11-20 11-Aminoalkyl- and 11-cyclicaminomorphanthridines

Publications (1)

Publication Number Publication Date
US3894001A true US3894001A (en) 1975-07-08

Family

ID=26976008

Family Applications (1)

Application Number Title Priority Date Filing Date
US307933A Expired - Lifetime US3894001A (en) 1969-08-07 1972-11-20 11-Aminoalkyl- and 11-cyclicaminomorphanthridines

Country Status (1)

Country Link
US (1) US3894001A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2624487A1 (en) * 1976-06-01 1977-12-15 Richardson Merrell Inc 11-Amino-alkyl-morphanthridine derivatives - with selective antidepressant activity
US4117122A (en) * 1974-11-25 1978-09-26 Richardson-Merrell Inc. 11-aminoalkylmorphanthridin-11-ols
US4434171A (en) 1980-11-28 1984-02-28 Sandoz Ltd. Dibenzazepine derivatives, pharmaceutical compositions containing them, and pharmaceutical methods using them
CN108331546A (en) * 2018-02-11 2018-07-27 义乌市绿美生物科技有限公司 A kind of novel oilfield chemicals equipment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3317537A (en) * 1965-06-25 1967-05-02 Colgate Palmolive Co Piperazinoalkyl-morphanthridines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3317537A (en) * 1965-06-25 1967-05-02 Colgate Palmolive Co Piperazinoalkyl-morphanthridines

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117122A (en) * 1974-11-25 1978-09-26 Richardson-Merrell Inc. 11-aminoalkylmorphanthridin-11-ols
DE2624487A1 (en) * 1976-06-01 1977-12-15 Richardson Merrell Inc 11-Amino-alkyl-morphanthridine derivatives - with selective antidepressant activity
US4434171A (en) 1980-11-28 1984-02-28 Sandoz Ltd. Dibenzazepine derivatives, pharmaceutical compositions containing them, and pharmaceutical methods using them
CN108331546A (en) * 2018-02-11 2018-07-27 义乌市绿美生物科技有限公司 A kind of novel oilfield chemicals equipment
CN108331546B (en) * 2018-02-11 2018-11-20 义乌市绿美生物科技有限公司 A kind of novel oilfield chemicals equipment

Similar Documents

Publication Publication Date Title
DE2760372C2 (en)
DE2915318C2 (en)
CH667657A5 (en) CARBOCYCLIC AND HETEROCYCLIC CARBONYL METHYLENE AND METHYL PIPERIDINE AND PYRROLIDINE.
US3681357A (en) 2-CHLORO-11-(PIPERAZINYL)DIBENZ{8 b,f{9 {8 1,4{9 OXAZEPINE AND ACID ADDITION SALTS THEREOF
US3712898A (en) Benzoheterocyclicalkyl derivatives of 4-(2-keto-1-benzimidazolinyl)-piperidine
IE44330B1 (en) 1-aminoalkanoyl-2-(10,11-dihydrodibenz /b,f//1,4/oxazepine-10-carbonyl)hydrazines.
US5646303A (en) Method for controlling emesis caused by chemotherapeutic agents and antiemetic agents useful therein
US4434171A (en) Dibenzazepine derivatives, pharmaceutical compositions containing them, and pharmaceutical methods using them
US3928356A (en) 10-{8 4-({107 -Hydroxy alkyl)-1-piperazimyl{9 -dibenzo (h,f) oxofins and thiepins and acetyl esters thereof
US4335126A (en) 1-[3-(3,4,5-Trimethoxyphenoxy)-2-hydroxy-propyl]-4-aryl-piperazine-derivatives having pharmaceutical activity
US3894001A (en) 11-Aminoalkyl- and 11-cyclicaminomorphanthridines
US3803154A (en) 11-cyclicaminoalkylidenemorphanthridines
US2918406A (en) Anti-spasmodics specific for peptic ulcer
DE1801523A1 (en) New Tricyclic Enamines and Processes for Making New Tricyclic Enamines
US3699099A (en) 11-aminoalkylidenemorphanthridines
US3859439A (en) 2,3-dihydro-5 -trifluoromethyl-1h-dibenzo(2,3:6,7) thiepino (4,5-c) pyrroles as cns-depressants
US3489836A (en) 5-amino - 10,11-dihydro - 5h - dibenzo (a,d)-cycloheptenes and derivatives in pharmaceutical compositions and the use thereof for the treatment of epilepsy
DE69617001T2 (en) (2-morpholinylmethyl) benzamide derivatives
US3767659A (en) Derivatives of 3,4-dihydrobenzothieno(2,3-c)pyridine
US3632653A (en) Ethano-anthracenes
EP0270692A1 (en) Antiarrhythmic agent
US3753992A (en) Process and intermediates for quinine,quinidine and derivatives thereof
US3435042A (en) Novel morphanthridine derivatives
DE2548668A1 (en) NEW NAPHTHALINE COMPOUNDS, METHODS OF MANUFACTURING THEM AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US3282943A (en) N-substitution products of polymethylene-tetrahydroquinolines